ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical
stage specialty biopharmaceutical company developing first-in-class
drugs for treatment of inflammatory and renal diseases, announces
publication of a paper in the peer-reviewed Journal of Clinical
Investigation highlighting how inflammation in the kidneys can
trigger inflammation in the heart.
In the paper titled, “Chronic kidney disease promotes atrial
fibrillation via inflammasome pathway activation,” the authors
conducted a study in mouse models of CKD and in-vitro studies with
serum from CKD patients and atrial samples from CKD and other
patients undergoing open heart surgery. Data from the research
indicate that CKD creates a substrate (IL-1β) that activates NLRP3
inflammasomes in the heart’s atria triggering damaging inflammation
associated with adverse atrial remodeling and dysfunction leading
to AF.
The authors stated, “Together, these findings support the idea
that CKD-induced systemic inflammatory factors activate the atrial
NLRP3 inflammasome thereby promoting the onset of AF. This
hypothesis is supported by the fact that genetic ablation of NLRP3
protected against abnormal atrial activation, atrial fibrosis and
atrial enlargement induced by CKD.” To read the article, Click
Here.
ZyVersa is developing Inflammasome ASC Inhibitor IC 100 to
inhibit multiple inflammasomes, including NLRP3, and their
associated ASC specs to attenuate release and perpetuation of
circulating IL-1β to control inflammation in various inflammatory
diseases.
“The research published in The Journal of Clinical Investigation
reinforces the importance of attenuating extracellular propagation
of IL-1β to minimize induction and perpetuation of inflammation in
surrounding tissues,” commented Stephen C. Glover, ZyVersa’s
Co-founder, Chairman, CEO, and President. “ZyVersa’s Inflammasome
ASC inhibitor IC 100 is designed to inhibit formation of multiple
types of inflammasomes to attenuate initiation of the inflammatory
cascade, and to inhibit their associated ASC specks to reduce
perpetuation of damaging inflammation.” To review a white paper
summarizing the mechanism of action and preclinical data for IC
100, Click Here.
About Inflammasome ASC Inhibitor IC 100
IC 100 is a novel humanized IgG4 monoclonal antibody that
inhibits the inflammasome adaptor protein ASC. IC 100 was designed
to attenuate both initiation and perpetuation of the inflammatory
response. It does so by binding to a specific region of the ASC
component of multiple types of inflammasomes, including NLRP1,
NLRP2, NLRP3, NLRC4, AIM2, Pyrin. Intracellularly, IC 100 binds to
ASC monomers, inhibiting inflammasome formation, thereby blocking
activation of IL-1β early in the inflammatory cascade. IC 100 also
binds to ASC in ASC Specks, both intracellularly and
extracellularly, further blocking activation of IL-1β and the
perpetuation of the inflammatory response that is pathogenic in
inflammatory diseases. Because active cytokines amplify adaptive
immunity through various mechanisms, IC 100, by attenuating
cytokine activation, also attenuates the adaptive immune
response.
About ZyVersa Therapeutics, Inc.
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty
biopharmaceutical company leveraging advanced, proprietary
technologies to develop first-in-class drugs for patients with
renal and inflammatory diseases who have significant unmet medical
needs. The Company is currently advancing a therapeutic development
pipeline with multiple programs built around its two proprietary
technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment
of kidney diseases, and Inflammasome ASC Inhibitor IC 100,
targeting damaging inflammation associated with numerous CNS and
other inflammatory diseases. For more information, please visit
www.zyversa.com.
Cautionary Statement Regarding Forward-Looking
Statements
Certain statements contained in this press release regarding
matters that are not historical facts, are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. These include statements regarding
management’s intentions, plans, beliefs, expectations, or forecasts
for the future, and, therefore, you are cautioned not to place
undue reliance on them. No forward-looking statement can be
guaranteed, and actual results may differ materially from those
projected. ZyVersa Therapeutics, Inc (“ZyVersa”) uses words such as
“anticipates,” “believes,” “plans,” “expects,” “projects,”
“future,” “intends,” “may,” “will,” “should,” “could,” “estimates,”
“predicts,” “potential,” “continue,” “guidance,” and similar
expressions to identify these forward-looking statements that are
intended to be covered by the safe-harbor provisions. Such
forward-looking statements are based on ZyVersa’s expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including ZyVersa’s plans to develop
and commercialize its product candidates, the timing of initiation
of ZyVersa’s planned preclinical and clinical trials; the timing of
the availability of data from ZyVersa’s preclinical and clinical
trials; the timing of any planned investigational new drug
application or new drug application; ZyVersa’s plans to research,
develop, and commercialize its current and future product
candidates; the clinical utility, potential benefits and market
acceptance of ZyVersa’s product candidates; ZyVersa’s
commercialization, marketing and manufacturing capabilities and
strategy; ZyVersa’s ability to protect its intellectual property
position; and ZyVersa’s estimates regarding future revenue,
expenses, capital requirements and need for additional
financing.
New factors emerge from time-to-time, and it is not possible for
ZyVersa to predict all such factors, nor can ZyVersa assess the
impact of each such factor on the business or the extent to which
any factor, or combination of factors, may cause actual results to
differ materially from those contained in any forward-looking
statements. Forward-looking statements included in this press
release are based on information available to ZyVersa as of the
date of this press release. ZyVersa disclaims any obligation to
update such forward-looking statements to reflect events or
circumstances after the date of this press release, except as
required by applicable law.
This press release does not constitute an offer to sell, or the
solicitation of an offer to buy, any securities.
Corporate and IR Contact:Karen CashmereChief
Commercial
Officerkcashmere@zyversa.com786-251-9641
Media ContactsTiberend Strategic Advisors,
Inc.Casey McDonaldcmcdonald@tiberend.com646-577-8520
Dave Schemeliadschemelia@tiberend.com609-468-9325
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Apr 2024 to May 2024
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From May 2023 to May 2024